Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05955872 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147
A Phase 1 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT05955872 is a Phase 1 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 21 participants.
The verdict
NCT05955872, a Phase 1 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the relative bioavailability (BA) and the effect of food on the pharmacokinetics (PK), and the safety and tolerability of VX-147 test tablet formulation.
Interventions
- DRUG VX-147
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2023-07-19 |
| Est. Completion | 2023-09-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05955872
The ClinicalTrials.gov registry entry for NCT05955872 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VX-147 is the first listed.
NCT05955872 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05955872 about?
NCT05955872 is a clinical study titled "A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147". The purpose of the study is to evaluate the relative bioavailability (BA) and the effect of food on the pharmacokinetics (PK), and the safety and tolerability of VX-147 test tablet formulation.
What is the current status of trial NCT05955872?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2023-07-19. Estimated completion is 2023-09-02.
What interventions are being tested in trial NCT05955872?
The interventions under investigation include: VX-147 (DRUG).
Who is sponsoring clinical trial NCT05955872?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.